Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Polycystic Ovary Syndrome 2Weight Gain 1Diabetes Mellitus, Type 2 1

Interventions

relacorilant 4Resistance Training 3Pioglitazone 3Dipeptidyl-Peptidase IV Inhibitors 3Sulfonylurea Compounds 2Rosiglitazone 2Nutritional Status 2Metformin 2voglibose 1saxagliptin 1repaglinide 1pembrolizumab 1miglitol 1metahexamide 1meglitinide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1Vildagliptin 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1Surveys and Questionnaires 1Sodium-Glucose Transporter 2 Inhibitors 1Sitagliptin Phosphate 1Resistant Starch 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diabetes Mellitus, Type 2 × empagliflozin × Clear all
NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

Completed
344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡